Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive ...

The European Commission’s plan to use joint procurement to provide access to innovative drugs across the bloc risks overuse ...

Following the release on the 14th of the **‘Joint Fact Sheet, the Joint Explanatory Document’**, which outlines the results ...

This case study demonstrates how advanced NMR spectroscopy enables high-resolution structural characterization of exenatide.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

An advocate for women’s reproductive health, she started one of the world’s smallest pharmaceutical companies to bring an ...

Selhorn provided a breakeven analysis: "Assuming gross margins in this mid to high 60% range, that puts our breakeven at about $17.3 million of net revenue per quarter all in, including EXXUA spends.

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential ...